GW Pharmaceuticals PLC /zigman2/quotes/209686240/composite GWPH +0.36% shares rose 2.6% in the extended session Monday after the U.K.-based company sold much more of its cannabis derived epilepsy drug, Epidiolex. The company reported a first-quarter net loss of $8 million, or 2 cents a share, compared with a loss of $50.1 million, or 14 cents a share, a year ago. Revenue rose to $120.6 million from $39.2 million in the year-ago period. The company's most popular drug, a cannabis-derived medicine used to treat epilepsy, logged sales of $116.1 million, topping analyst expectations of $106.9 million, according to FactSet's survey. Wall Street expected an adjusted net loss of 7 cents a share on sales of $108.4 million. GW Pharma stock has inched up 4.7% this year as the benchmark S&P 500 index /zigman2/quotes/210599714/realtime SPX +1.95% has fallen 9.3%.